BRAF‐mutated CRC has a poor prognosis; however, cases exhibiting deficient MMR (dMMR)/MSI‐high (MSI‐H) and BRAF gene mutations have demonstrated significant prognostic improvement following recent immune checkpoint inhibitor therapy. The gene discussed is BRAF; the disease is colorectal carcinoma.